BWI: Sun Pharma Announces USFDA Approval for Generic Prometh® Syrup

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Thursday, March 18, 2010 02:17 PM IST (08:47 AM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
--------------------------------------------------
Sun Pharma Announces USFDA Approval for Generic Prometh® Syrup


Mumbai, Maharashtra, India, Thursday, March 18, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml.

This Promethazine Hydrochloride with Codeine Phosphate Oral Syrup is bioequivalent to Prometh® w/ Codeine of Actavis Mid Atlantic LLC. This product has annual sales of approximately USD 16 million in the US.

This medication is used to treat symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis).

Prometh® is the registered trademark of Actavis Mid Atlantic LLC.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

You have received this email as your address is part of our Investor Relations and Media Contacts list. All our Press Releases and Financial updates are sent to those on the list.

-- If you wish to be removed from this list or your address has been accidentally included here, then please let us know by a return email and we will remove it. All the others will continue to be on the mailing list.

-- If you wish to receive emails on some other email id, please send it to us.

-- If you think that somebody else from your organisation should be added to this list, then please ask him / her to send us an email and we will add.

-- If you are changing jobs, please send us your new email id. We would like to be in touch with you and keep you updated on happenings at Sun Pharma.

We would be happy to host one-on-one, group and telephone meetings for updates on the Company. If you wish to setup such a meeting, feel free to get in touch with us. In-person meetings can be at our office or elsewhere depending on mutual convenience.


CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Ext 605/ +91 (22) 66455605/ +91 9867010529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 66455645, Ext 606/ +91 (22) 66455606/ +91 9821923797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE, SUNPHARMA.BO, SUNPHARMA .NS

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com